211 related articles for article (PubMed ID: 36232292)
1. Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.
Winzer EB; Schauer A; Langner E; Augstein A; Goto K; Männel A; Barthel P; Jannasch A; Labeit S; Mangner N; Linke A; Adams V
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232292
[TBL] [Abstract][Full Text] [Related]
2. Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility.
Adams V; Schauer A; Augstein A; Kirchhoff V; Draskowski R; Jannasch A; Goto K; Lyall G; Männel A; Barthel P; Mangner N; Winzer EB; Linke A; Labeit S
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1565-1581. PubMed ID: 35301823
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain.
Schauer A; Adams V; Kämmerer S; Langner E; Augstein A; Barthel P; Männel A; Fabig G; Alves PKN; Günscht M; El-Armouche A; Müller-Reichert T; Linke A; Winzer EB
Circ Heart Fail; 2024 Jun; 17(6):e011107. PubMed ID: 38847102
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Titin and Contraction-Regulating Proteins in a Rat Model of Heart Failure with Preserved Ejection Fraction: Limb vs. Diaphragmatic Muscle.
Vahle B; Heilmann L; Schauer A; Augstein A; Jarabo MP; Barthel P; Mangner N; Labeit S; Bowen TS; Linke A; Adams V
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928324
[TBL] [Abstract][Full Text] [Related]
6. Exercise Training Reveals Inflexibility of the Diaphragm in an Animal Model of Patients With Obesity-Driven Heart Failure With a Preserved Ejection Fraction.
Bowen TS; Brauer D; Rolim NPL; Bækkerud FH; Kricke A; Ormbostad Berre AM; Fischer T; Linke A; da Silva GJ; Wisloff U; Adams V
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066440
[TBL] [Abstract][Full Text] [Related]
7. Effects of homoarginine supplementation on heart and skeletal muscle of rats with heart failure with preserved ejection fraction.
Büttner P; Adams V; Werner S; Ossmann S; Besler C; Schwedhelm E; Thiele H
ESC Heart Fail; 2022 Dec; 9(6):4348-4351. PubMed ID: 36043453
[TBL] [Abstract][Full Text] [Related]
8. ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction.
Schauer A; Draskowski R; Jannasch A; Kirchhoff V; Goto K; Männel A; Barthel P; Augstein A; Winzer E; Tugtekin M; Labeit S; Linke A; Adams V
ESC Heart Fail; 2020 Oct; 7(5):2123-2134. PubMed ID: 32710530
[TBL] [Abstract][Full Text] [Related]
9. Muscular changes in animal models of heart failure with preserved ejection fraction: what comes closest to the patient?
Goto K; Schauer A; Augstein A; Methawasin M; Granzier H; Halle M; Craenenbroeck EMV; Rolim N; Gielen S; Pieske B; Winzer EB; Linke A; Adams V
ESC Heart Fail; 2021 Feb; 8(1):139-150. PubMed ID: 33350094
[TBL] [Abstract][Full Text] [Related]
10. Abnormal skeletal muscle blood flow, contractile mechanics and fibre morphology in a rat model of obese-HFpEF.
Espino-Gonzalez E; Tickle PG; Benson AP; Kissane RWP; Askew GN; Egginton S; Bowen TS
J Physiol; 2021 Feb; 599(3):981-1001. PubMed ID: 33347612
[TBL] [Abstract][Full Text] [Related]
11. Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism.
Zamani P; Proto EA; Wilson N; Fazelinia H; Ding H; Spruce LA; Davila A; Hanff TC; Mazurek JA; Prenner SB; Desjardins B; Margulies KB; Kelly DP; Arany Z; Doulias PT; Elrod JW; Allen ME; McCormack SE; Schur GM; D'Aquilla K; Kumar D; Thakuri D; Prabhakaran K; Langham MC; Poole DC; Seeholzer SH; Reddy R; Ischiropoulos H; Chirinos JA
ESC Heart Fail; 2021 Aug; 8(4):2698-2712. PubMed ID: 33991175
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
[TBL] [Abstract][Full Text] [Related]
14. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
Nambu H; Takada S; Fukushima A; Matsumoto J; Kakutani N; Maekawa S; Shirakawa R; Nakano I; Furihata T; Katayama T; Yamanashi K; Obata Y; Saito A; Yokota T; Kinugawa S
Eur J Pharmacol; 2020 Jan; 866():172810. PubMed ID: 31738936
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin directly improves diastolic function in human heart failure.
Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
[TBL] [Abstract][Full Text] [Related]
18. Effects of Endurance Training on Detrimental Structural, Cellular, and Functional Alterations in Skeletal Muscles of Heart Failure With Preserved Ejection Fraction.
Bowen TS; Herz C; Rolim NPL; Berre AO; Halle M; Kricke A; Linke A; da Silva GJ; Wisloff U; Adams V
J Card Fail; 2018 Sep; 24(9):603-613. PubMed ID: 30195827
[TBL] [Abstract][Full Text] [Related]
19. Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition.
Alves PKN; Schauer A; Augstein A; Männel A; Barthel P; Joachim D; Friedrich J; Prieto ME; Moriscot AS; Linke A; Adams V
Cells; 2023 Nov; 12(21):. PubMed ID: 37947639
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
